Monograph Details
|
|
Urogenital System
> Overactive bladder/enuresis
|
|
DDAVP |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Vasopressin (synthetic). |
| Generic Name |
|
Desmopressin acetate 0.1mg, 0.2mg; scored tabs. |
| Also |
• DDAVP INJECTION
• DDAVP NASAL SPRAY
• DDAVP RHINAL TUBE
|
| Indications |
|
Primary nocturnal enuresis. |
| Adults and Children |
|
<6yrs: not recommended. 6–17yrs: initially 0.2mg once daily at bedtime; individualize; max 0.6mg. When switching to tabs give 1st oral dose 24 hrs after last intranasal dose. |
| Precautions |
|
Monitor fluid intake, urine volume and osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Coronary artery insufficiency. Hypertension. Nasal mucosal changes may cause unreliable absorption; discontinue use until nasal problems resolve (nasal forms). Very young. Elderly. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with other pressor agents. |
| Adverse Reactions |
|
Headache, nausea, nasal congestion, rhinitis, flushing, abdominal cramps, water intoxication, hyponatremia, changes in blood pressure, epistaxis, sore throat, cough; seizures in children from plasma hypoosmolality (rare). |
| How Supplied |
Tabs—100
Nasal spray—5 mL (50 sprays)
Rhinal tube—2.5 mL (w. 2 rhinal tubes) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
